Half- and mixed-sandwich metallacarboranes for potential applications in medicine
Author:
Gozzi Marta1ORCID, Schwarze Benedikt1ORCID, Hey-Hawkins Evamarie2ORCID
Affiliation:
1. Universität Leipzig, Institut für Anorganische Chemie , Johannisallee 29 , 04103 Leipzig , Germany 2. Universität Leipzig, Institut für Anorganische Chemie , Johannisallee 29 , 04103 Leipzig , Germany , Phone: +49-341-9736151, Fax: +49-341-9739319
Abstract
Abstract
Today, medicinal chemistry is still clearly dominated by organic chemistry, and commercially available boron-based drugs are rare. In contrast to hydrocarbons, boranes prefer the formation of polyhedral clusters via delocalized 3c2e bonds, such as polyhedral dicarba-closo-dodecaborane(12) (closo-C2B10H12). These clusters have remarkable biological stability, and the three isomers, 1,2- (ortho), 1,7- (meta), and 1,12-dicarba-closo-dodecaborane(12) (para), have attracted much interest due to their unique structural features. Furthermore, anionic nido clusters ([7,8-C2B9H11]2−), derived from the neutral icosahedral closo cluster 1,2-dicarba-closo-dodecaborane(12) by deboronation followed by deprotonation are suitable ligands for transition metals and offer the possibility to form metallacarboranes, for example via coordination through the upper pentagonal face of the cluster. The isolobal analogy between the cyclopentadienyl(–1) ligand (Cp−) and [C2B9H11]2− clusters (dicarbollide anion, Cb2−) is the motivation in using Cb2− as ligand for coordination to a metal center to design compounds for various applications. This review focuses on potential applications of half- and mixed-sandwich-type transition metal complexes in medicine.
Funder
Verband der Chemischen Industrie Sächsisches Staatsministerium für Wissenschaft und Kunst
Publisher
Walter de Gruyter GmbH
Subject
General Chemical Engineering,General Chemistry
Reference102 articles.
1. B. Jones, S. Adams, G. T. Miller, M. I. Jesson, T. Watanabe, B. P. Wallner. Blood102, 1641 (2003). 2. Bortezomib: B. A. Teicher, G. Ara, R. Herbst, V. J. Palombella, J. Adams. Clin. Cancer Res.5, 2638 (1999). 3. Bortezomib: E. S. Lightcap, T. A. McCormack, C. S. Pien, V. Chau, J. Adams, P. J. Elliott. Clin. Chem.46, 673 (2000). 4. Bortezomib: T. Hideshima, P. Richardson, D. Chauhan, V. J. Palombella, P. J. Elliott, J. Adams, K. C. Anderson. Cancer Res.61, 3071 (2001). 5. Bortezomib: J. Adams, M. Behnke, S. W. Chen, A. A. Cruickshank, L. R. Dick, L. Grenier, J. M. Klunder, Y. T. Ma, L. Plamondon, R. L. Stein. Bioorg. Med. Chem. Lett.8, 333 (2016).
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|